When you read the Pharma news sites and analysis on LinkedIn about drug patent cliffs, you might think pharmaceutical companies are sitting […]
Introduction: Spotting the Threat You Didn’t Expect This week’s article is based on a project I completed earlier this year as part […]
Early this week, I joined Chris Spivey on PharmaTech.com’s Behind the Headlines to discuss several of the previous week’s significant life science […]
~1.5 years ago I was reading a Financial Times article (FT.com) on obesity drugs and their order to market when my critical […]
Following last week’s post on the slow activity in M&A in 2025 so far (Sivan-Consulting), we now have some activity picking up, […]
It has been a bit of a writing hiatus as I have been in the middle of delivering a few short, intense […]
This post/article is worth a read for those interested in the evolution of Pharma Business models: Pharma Exec – The Teva Turnaround […]
This follows last week’s post (Link) on the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies, based […]
I recently read an interesting paper from Prof. Alexander Schuhmacher et al. on the impact of M&A and licensing on FDA drug […]
1. Introduction In this project history, I’ll talk about an example of a proactive company preparing for an event several years away, […]